Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
Genmab A/S (Nasdaq: GMAB) said worldwide net trade sales of DARZALEX (daratumumab), including the subcutaneous DARZALEX FASPRO, were $4,207 million in Q2 2026, with $2,435 million in the U.S. and $1,772 million in other regions, as reported by Johnson & Johnson (Janssen). Genmab earns royalties on worldwide net sales under its license to J&J.
How this was made
The 30-second read
Why it matters
The disclosed Q2 2026 net trade sales figure updates the royalty base for Genmab, which can affect earnings expectations and valuation for investors tracking royalty revenue durability.
Market read
A concrete quarterly sales datapoint for daratumumab, relevant mainly through Genmab’s royalty economics.
What to watch
No context is provided versus prior quarters or consensus, and the article does not clarify whether SC mix or pricing changes drove the quarter.
Background
Genmab licenses daratumumab (DARZALEX IV and DARZALEX FASPRO SC) to Johnson & Johnson and receives royalties on worldwide net sales reported by J&J.
Ticker impact
Genmab reports DARZALEX worldwide net trade sales of USD 4,207 million for Q2 2026, with U.S. and ex-U.S. splits.
Likely modest near-term impact, as it is a royalty-linked sales datapoint rather than Genmab standalone product revenue.
The article provides a specific quarterly sales figure and geographic breakdown, but it does not include guidance, consensus comparison, or incremental operational changes.
Market effects
Biopharma royalty streams tied to partner-reported sales can influence sentiment around antibody oncology demand.
Limited, as the disclosure is global and royalty-based rather than region-specific operations.
Moderate for oncology antibody investors tracking daratumumab demand and partner sales trends.
Counterpoint
Because Genmab’s royalty depends on J&J-reported net trade sales, the print may be less predictive of Genmab’s own near-term fundamentals than investors expect.
Key entities
- companyGenmab A/S
Reports Q2 2026 worldwide net trade sales of DARZALEX (daratumumab) as reported by J&J, and reiterates its royalty arrangement.
- productDARZALEX (daratumumab)
Antibody medicine whose IV and SC net trade sales drive Genmab royalties under the J&J license.
- counterpartyJohnson & Johnson (Janssen Biotech, Inc.)
Reports the net trade sales figures used for Genmab’s worldwide royalty calculations.
